Log in

Relevant bibliographies by topics / Drug development / Journal articles

To see the other types of publications on this topic, follow the link: Drug development.

Journal articles on the topic 'Drug development'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Drug development.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Mishra, Hara Prasad, Ayush Goel, Sahil Kumar, Mihir Chauhan, Mrinal Patnaik, and Imaad Rehman. "Drug development hit by war." Journal of Pharmacovigilance and Drug Research 3, no. 2 (2022): 11–15. http://dx.doi.org/10.53411/jpadr.2022.3.2.3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Jadhav, Mr Gahininath Thansing, and Mr Rahul Bhavlal Jadhav. "Drug Discovery and Development Process." International Journal of Research Publication and Reviews 5, no. 1 (2024): 1891–95. http://dx.doi.org/10.55248/gengpi.5.0124.0225.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Sheela, Thorat* Sunita Patil Shubhangi Mali. "Pro-Drug Development." International Journal of Pharmaceutical Sciences 3, no. 3 (2025): 1234–43. https://doi.org/10.5281/zenodo.15019692.

Full text

Abstract:

Prodrugs can provide a flexible approach to enhance the efficacy or safety profile, as well as the poor pharmaceutical and pharmacokinetic features of potential therapeutic candidates as well as, in some situations, clinically authorized drugs. As the prodrugs are inactive form of the drugs which undergoes the metabolism it gives the formation of active compounds which is responsible for the therapeutic activity of drug. Right now the prodrug has more attention in the drug discovery and development. The current article focuses on the overview study of prodrugs like the definition, classificati

APA, Harvard, Vancouver, ISO, and other styles

4

Adukondalu, D., Rajesh Rajesh, Shaik Thaslim, E. Soumya, and M. Chandana. "Regulatory Guidelines for New Drug Development." Pharmaceutics and Pharmacology Research 4, no. 3 (2021): 01–11. http://dx.doi.org/10.31579/2693-7247/046.

Full text

Abstract:

Aim: The aim of present project work is to understand the guidelines and regulatory requirements for investigational new drug and development of new drug Objectives: The objective of current project include Need of a new drug to investigate New drug development targets Understanding the properties of new dug Required protocols for submission of new drug to regulatory authority Regulatory requirements to get approval of new drug.

APA, Harvard, Vancouver, ISO, and other styles

5

Sharma, Bhavik. "DRUG DISCOVERY AND DEVELOPMENT: AN OVERVIEW." INDIAN RESEARCH JOURNAL OF PHARMACY AND SCIENCE 7, no. 2 (2020): 2215–26. http://dx.doi.org/10.21276/irjps.2020.7.2.14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Agrawal, Shrutidevi, Narisetty Sunil Thomas, Anand Babu Dhanikula, Chaman Lal Kaul, and Ramesh Panchagnula. "Antituberculosis drugs and new drug development." Current Opinion in Pulmonary Medicine 7, no. 3 (2001): 142–47. http://dx.doi.org/10.1097/00063198-200105000-00005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

GRABOWSKI, H. G. "Issues of Drug Development: Orphan Drugs." Science 228, no. 4702 (1985): 981. http://dx.doi.org/10.1126/science.228.4702.981.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Vaalburg, Willem, N. Harry Hendrikse, and Erik F. J. de Vries. "Drug development, radiolabeled drugs and PET." Annals of Medicine 31, no. 6 (1999): 432–37. http://dx.doi.org/10.3109/07853899908998801.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Flaherty, Keith T., Dung T. Le, and Steven Lemery. "Tissue-Agnostic Drug Development." American Society of Clinical Oncology Educational Book, no. 37 (May 2017): 222–30. http://dx.doi.org/10.1200/edbk_173855.

Full text

Abstract:

The U.S. Food and Drug Administration (FDA) has approved drugs to treat patients with tumor types based on a single anatomic site, such as renal cell carcinoma or melanoma, rather than on a biomarker alone. This standard approach is based on a number of factors, including heterogeneity of drug effects in different biomarker-positive tumor types. Additionally, drug development for some drugs was primarily directed toward a specific genomic abnormality in a specific tumor type (e.g., drugs for anaplastic lymphoma kinase [ALK] fusion-positive non–small cell lung cancer). In such cases, difference

APA, Harvard, Vancouver, ISO, and other styles

10

Yamashiro, Yuichiro, Jennifer Martin, Madlen Gazarian, et al. "Drug Development." Journal of Pediatric Gastroenterology and Nutrition 55, no. 5 (2012): 506–10. http://dx.doi.org/10.1097/mpg.0b013e318272af1f.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Williams, Ian. "Drug Development." Science 277, no. 5322 (1997): 17.6–21. http://dx.doi.org/10.1126/science.277.5322.17-f.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Williams;, I. "Drug Development." Science 277, no. 5322 (1997): 17e—21. http://dx.doi.org/10.1126/science.277.5322.17e.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

BRENNAN, MAIRIN. "DRUG DEVELOPMENT." Chemical & Engineering News 74, no. 44 (1996): 10. http://dx.doi.org/10.1021/cen-v074n044.p009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

HENRY, CELIA M. "DRUG DEVELOPMENT." Chemical & Engineering News 80, no. 21 (2002): 53–66. http://dx.doi.org/10.1021/cen-v080n021.p053.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

K. Kapoor, Vijay, and Amanpreet Kaur. "Drug-Glycosidation and Drug Development." Mini-Reviews in Medicinal Chemistry 13, no. 4 (2013): 584–96. http://dx.doi.org/10.2174/1389557511313040010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Komatsu, Kanji. "Statistical Models for Model-Based Drug Development." Japanese Journal of Biometrics 32, Special_Issue_2 (2011): 179–93. http://dx.doi.org/10.5691/jjb.32.179.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Bhusare, Shubham, Ms Dipmala Ghorpade, and Dr Gajanan Sanap. "Artificial Intelligence in Drug Discovery and Development." International Journal of Research Publication and Reviews 6, no. 1 (2025): 1096–106. https://doi.org/10.55248/gengpi.6.0125.0307.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Garepally, Prasad, Swathi Goli, and Vijay Kumar Bontha. "Design, Development and Characterizations of Acyclovir Osmotic Tablets." Pharmaceutics and Pharmacology Research 1, no. 1 (2018): 01–14. http://dx.doi.org/10.31579/2693-7247/005.

Full text

Abstract:

Oral drug delivery is the most widely utilized route of administration, among all the routes of administration. That has been explored for the systemic delivery drug through different pharmaceutical dosage forms. It can be said that at least 90%of all drugs used to produce systemic effect is by oral route. Conventional oral drug delivery systems are known to provide an immediate release of drug, in which one cannot control the release of the drug and effective concentration at the target site.

APA, Harvard, Vancouver, ISO, and other styles

19

DiMasi, Joseph A., and Henry G. Grabowski. "Economics of New Oncology Drug Development." Journal of Clinical Oncology 25, no. 2 (2007): 209–16. http://dx.doi.org/10.1200/jco.2006.09.0803.

Full text

Abstract:

Purpose Review existing studies and provide new results on the development, regulatory, and market aspects of new oncology drug development. Methods We utilized data from the US Food and Drug Administration (FDA), company surveys, and publicly available commercial business intelligence databases on new oncology drugs approved in the United States and on investigational oncology drugs to estimate average development and regulatory approval times, clinical approval success rates, first-in-class status, and global market diffusion. Results We found that approved new oncology drugs to have a dispr

APA, Harvard, Vancouver, ISO, and other styles

20

Drews, Jürgen, and Stefan Ryser. "Drug Development: The role of innovation in drug development." Nature Biotechnology 15, no. 13 (1997): 1318–19. http://dx.doi.org/10.1038/nbt1297-1318.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Kusuhara, Hiroyuki. "Development of endogenous biomarkers to assess drug-transporter-mediated drug-drug interactions in drug development." Proceedings for Annual Meeting of The Japanese Pharmacological Society 94 (2021): 3—S32–4. http://dx.doi.org/10.1254/jpssuppl.94.0_3-s32-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

AMIN, Dipti, and Jean-Pierre ISAL. "Evaluation of Drug-Drug Interactions in Drug Development." Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 34, no. 1 (2003): 193S—194S. http://dx.doi.org/10.3999/jscpt.34.193s.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Gandhi, Karan, Umang Shah, and Sandip Patel. "Drug Stereochemistry: A Prodigy For Pharmacology and Drug Development." Current Drug Discovery Technologies 17, no. 5 (2020): 565–73. http://dx.doi.org/10.2174/1570163816666190502101803.

Full text

Abstract:

Stereochemistry has evinced the importance of many chiral drugs with respect to drug designing and development. A literature review was conducted for several chiral drugs involving pharmacokinetic and pharmacodynamic parameters of their enantiomers along with their uses in certain diseased conditions. This article mainly includes the pharmacological profile review of some chiral drugs and the aspects due to which the single enantiomer is of importance as compared to the racemic mixture of the drug. This was achieved by moderating the side effects or toxic effects; or by the potentiated activit

APA, Harvard, Vancouver, ISO, and other styles

24

Rehan Haider, Asghar Mehdi, Anjum Zehra, Geetha Kumari Das, Zameer Ahmed, and Sambreen Zameer. "Drug Development Research in Women." International Journal of Scientific Multidisciplinary Research 2, no. 5 (2024): 415–40. http://dx.doi.org/10.55927/ijsmr.v2i5.8807.

Full text

Abstract:

Drug research in wives is a critical district that has acquired growing consideration in recent ages. Historically, mothers have diminished in clinical tests, chief to a lack of understanding about in what way or manner drugs influence them otherwise distinguished to brothers. This information gap has important associations for drug security and efficiency, as physiological dissimilarities between genders can impact drug absorption, productiveness, and adverse belongings. In answer, skilled has existed a growing importance on containing girls in dispassionate trials and attending grammar princ

APA, Harvard, Vancouver, ISO, and other styles

25

Matsubara, Takashi. "Safety Evaluation and Drug Development based on Biological Fate of Drugs —Efforts Made to Overcome Drug Interaction in Drug Development—." Drug Metabolism and Pharmacokinetics 17, no. 5 (2002): 379–94. http://dx.doi.org/10.2133/dmpk.17.379.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Eunike, Seleky, Santoso Dedy, and Wisnubroto Aloysius. "The Development of Narcotics Legislation in Indonesia and Singapore." International Journal of Social Science And Human Research 06, no. 06 (2023): 3762–67. https://doi.org/10.5281/zenodo.8085856.

Full text

Abstract:

Since the Dutch colonial era, Indonesia has had drug-related regulations. Drug use was controlled with special licenses for people of Chinese descent who contributed financially through the opium trade. After Indonesia's independence, regulations on the production, use, and distribution of dangerous drugs were issued. In the 1970s, drug abuse increased, and the government responded with laws regulating illicit drug trafficking and imposing severe criminal sanctions, including the death penalty. During the Reformasi era, the crackdown on drugs became more assertive. BNN was established in 2

APA, Harvard, Vancouver, ISO, and other styles

27

Shafer, Robert W., and Jonathan M. Schapiro. "Drug resistance and antiretroviral drug development." Journal of Antimicrobial Chemotherapy 55, no. 6 (2005): 817–20. http://dx.doi.org/10.1093/jac/dki127.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

GAD, S. "Active drug metabolites in drug development." Current Opinion in Pharmacology 3, no. 1 (2003): 98–100. http://dx.doi.org/10.1016/s1471-4892(02)00003-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

GS, Lavekar. "Concept of Integrated Drugs Development." Journal of Natural & Ayurvedic Medicine 7, no. 3 (2023): 1–4. http://dx.doi.org/10.23880/jonam-16000413.

Full text

Abstract:

Drugs are an integral part of treatment in health care, it is a belief that the drugs should be free from side effects should be safe and not to create any disease. The chemical or allopathic drugs which are having some side effects may be combined with Ayurveda herbal drugs to pacify their side effects or bring to minimal level. Another aspect is that the Ayurved herbal drugs are slow and weak in action, but quite safe, on other side the allopathic drugs are comparatively fast, bit strong but with some side effects. If these two are combined like an example of anti-diabetic allopathic drug me

APA, Harvard, Vancouver, ISO, and other styles

30

Li, Xue, Xiaoming Fan, Zhu Li, et al. "Application of Microfluidics in Drug Development from Traditional Medicine." Biosensors 12, no. 10 (2022): 870. http://dx.doi.org/10.3390/bios12100870.

Full text

Abstract:

While there are many clinical drugs for prophylaxis and treatment, the search for those with low or no risk of side effects for the control of infectious and non-infectious diseases is a dilemma that cannot be solved by today’s traditional drug development strategies. The need for new drug development strategies is becoming increasingly important, and the development of new drugs from traditional medicines is the most promising strategy. Many valuable clinical drugs have been developed based on traditional medicine, including drugs with single active ingredients similar to modern drugs and tho

APA, Harvard, Vancouver, ISO, and other styles

31

Alderton, Gemma. "Diversifying drug development." Science 371, no. 6529 (2021): 580.9–582. http://dx.doi.org/10.1126/science.371.6529.580-i.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Field, Hugh J., and Mark A. Wainberg. "Antiviral drug development." Future Virology 6, no. 5 (2011): 545–47. http://dx.doi.org/10.2217/fvl.11.36.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Loadman, P. "Anticancer Drug Development." British Journal of Cancer 86, no. 10 (2002): 1665–66. http://dx.doi.org/10.1038/sj.bjc.6600309.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Vaughan Williams, E. M. "ANTIARRHYTHMIC DRUG DEVELOPMENT." American Journal of Therapeutics 2, no. 4 (1995): 233–36. http://dx.doi.org/10.1097/00045391-199504000-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Somberg, John C. "Pediatric Drug Development." American Journal of Therapeutics 10, no. 1 (2003): 2. http://dx.doi.org/10.1097/00045391-200301000-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Donnan, Geoffrey A., and Stephen M. Davis. "Stroke Drug Development." Stroke 36, no. 10 (2005): 2326. http://dx.doi.org/10.1161/01.str.0000179042.06535.2f.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Luetkemeyer, Anne F., Haileyesus Getahun, Gabriel Chamie, Christian Lienhardt, and Diane V. Havlir. "Tuberculosis Drug Development." American Journal of Respiratory and Critical Care Medicine 184, no. 10 (2011): 1107–13. http://dx.doi.org/10.1164/rccm.201106-0995pp.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Ades, Felipe, Dimitrios Zardavas, Philippe Aftimos, and Ahmad Awada. "Anticancer drug development." Current Opinion in Oncology 26, no. 3 (2014): 334–39. http://dx.doi.org/10.1097/cco.0000000000000076.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Preskorn, Sheldon H. "CNS Drug Development." Journal of Psychiatric Practice 16, no. 6 (2010): 413–15. http://dx.doi.org/10.1097/01.pra.0000390760.12204.99.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Preskorn, Sheldon H. "CNS Drug Development." Journal of Psychiatric Practice 17, no. 1 (2011): 49–52. http://dx.doi.org/10.1097/01.pra.0000393844.48593.82.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

PRESKORN, SHELDON H. "CNS Drug Development." Journal of Psychiatric Practice 20, no. 6 (2014): 460–65. http://dx.doi.org/10.1097/01.pra.0000456594.66363.6f.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

PRESKORN, SHELDON H. "CNS Drug Development." Journal of Psychiatric Practice 21, no. 1 (2015): 60–66. http://dx.doi.org/10.1097/01.pra.0000460622.33300.64.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Kaye, Stanley B. "New drug development." European Journal of Cancer and Clinical Oncology 27, no. 3 (1991): 377–80. http://dx.doi.org/10.1016/0277-5379(91)90550-w.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

McConnell, John. "Global drug development?" Lancet 341, no. 8848 (1993): 822. http://dx.doi.org/10.1016/0140-6736(93)90592-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Hoffman, Steven J., Thomas Pogge, and Aidan Hollis. "New drug development." Lancet 377, no. 9769 (2011): 901–2. http://dx.doi.org/10.1016/s0140-6736(11)60347-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Catalá-López, Ferrán, Anna García-Altés, Elena Álvarez-Martín, Ricard Gènova-Maleras, and Consuelo Morant-Ginestar. "New drug development." Lancet 377, no. 9769 (2011): 902. http://dx.doi.org/10.1016/s0140-6736(11)60348-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Walson, Philip D. "Pediatric Drug Development." Clinical Therapeutics 36, no. 2 (2014): 154–55. http://dx.doi.org/10.1016/j.clinthera.2014.01.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Novack, Gary D. "Ophthalmic Drug Development." Journal of Glaucoma 7, no. 3 (1998): 202???209. http://dx.doi.org/10.1097/00061198-199806000-00009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Katz, Linda M. "Nonprescription Drug Development." Drug Information Journal 28, no. 2 (1994): 449–51. http://dx.doi.org/10.1177/009286159402800218.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Schachter, Asher D., and Marco F. Ramoni. "Paediatric drug development." Nature Reviews Drug Discovery 6, no. 6 (2007): 429–30. http://dx.doi.org/10.1038/nrd2333.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!